Get the Stockscreener App
2.50
5.30%
-0.14
After Hours:
2.50
Xenetic Biosciences Inc stock is traded at $2.50, with a volume of 3,064.
It is down -5.30% in the last 24 hours and down -15.11% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
See More
Previous Close:
$2.64
Open:
$2.51
24h Volume:
3,064
Relative Volume:
0.19
Market Cap:
$5.73M
Revenue:
$3.19M
Net Income/Loss:
$-2.23M
P/E Ratio:
-2.0337
EPS:
-1.2293
Net Cash Flow:
$-1.82M
1W Performance:
-11.03%
1M Performance:
-15.11%
6M Performance:
-1.96%
1Y Performance:
-30.62%
1-Day Range:
$2.50
$2.5677
1-Week Range:
$2.4501
$2.9872
52-Week Range:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.50 | 6.05M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085 - TradingKey
Xenetic Biosciences Inc (XBIO) Cash Flow - TradingKey
Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Number of shareholders of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to revenue forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to earnings forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBITDA forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to sales forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBIT forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09Large Cap Trends - dars.gov.et
XBIOXenetic Biosciences Inc Latest SEC Filings - Finviz
Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO) - TradingView
Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenetic Biosciences Inc (XBIO) Institutional Confidence - TradingKey
Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenetic Biosciences (XBIO) Gains 6.7% – Bullish Breakout Within Tight RangeBreakout Stock Alerts - newsline.com
Xenetic Biosciences (XBIO) Holds Tight Range Near $3.10 with Minimal MovementFibonacci Time Zone - dars.gov.et
XBIO Q2 2025 Earnings: EPS Surpasses Estimates Despite No RevenueLong-Term Guidance - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss Beats Estimates, Yet Stock Slips on No Revenue ProgressAnalyst Coverage Count - dars.gov.et
Xenetic Biosciences (XBIO) Secures Approval for Clinical Study i - GuruFocus
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - ACCESS Newswire
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - BioSpace
Xenetic presents preclinical data on DNase I with CAR-T therapy - Investing.com Nigeria
Xenetic (XBIO) Reveals Promising Preclinical Results for CAR-T Therapy - GuruFocus
Xenetic presents preclinical data on DNase I with CAR-T therapy By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc.: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - FinanzNachrichten.de
After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case - Stock Titan
Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
XBIO Q2 2025 Earnings: Narrowed Loss Exceeds Expectations as Pipeline AdvancesEarnings Risk Report - dars.gov.et
Xenetic Biosciences (XBIO) Edges Lower Amid Tight Trading RangeKAMA Signal - dars.gov.et
Xenetic Biosciences (XBIO) Modestly Advances as Biotech Stock Tests Key Resistance ZoneVolume Climax - The Legal Advocate
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress - The Legal Advocate
Xenetic Biosciences (XBIO) Bounces 3.03%, Holding Above Key SupportBreakout Confirmation - newsline.com
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesPre-Earnings Drift - Newser
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update - Bez Kabli
XBIO Stock Price, Quote & Chart | XENETIC BIOSCIENCES INC (NASDAQ:XBIO) - ChartMill
Xenetic Biosciences (XBIO) Q2 2025 Earnings Roar: $-0.45 EPS Tops Street ViewCommunity Momentum Stocks - Newser
Xenetic Biosciences (XBIO) Declines -3.75% Amid Market Weakness 2026-05-18Community Watchlist Picks - Newser
Contact Us – Inside INdiana BusinessXenetic Biosciences, Inc.Common Stock (Nasdaq:XBIO) Stock Quote - FinancialContent
Renaissance Holdings Reports 137,440 XBIO Shares (NASDAQ: XBIO) - Stock Titan
Xenetic (XBIO) Reports Strong Q1 Revenue Growth - GuruFocus
Xenetic Virtually Unchanged - Baystreet.ca
Xenetic Biosciences Reports Q1 2026 Results: Advances DNase Oncology Platform, Grows Royalty Revenue, and Strengthens Financial Position - Minichart
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):